Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
28 mars 2023 07h30 HE
|
Vera Therapeutics
Announced positive interim data from the Phase 2b ORIGIN clinical trial of atacicept in IgAN, which showed a 41% mean reduction in proteinuria versus baseline in the 150mg dose group at 24...
Vera Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference
27 févr. 2023 16h05 HE
|
Vera Therapeutics
BRISBANE, Calif., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for...
Vera Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Class A Common Stock
06 févr. 2023 16h05 HE
|
Vera Therapeutics
BRISBANE, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NasdaqGM: VERA; “Vera”), a late-stage biotechnology company focused on developing and commercializing transformative...
Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock
01 févr. 2023 21h52 HE
|
Vera Therapeutics
BRISBANE, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc., (NasdaqGM: VERA; “Vera”), a late-stage biotechnology company focused on developing and commercializing transformative...
Vera Therapeutics Announces Commencement of Public Offering of Class A Common Stock
01 févr. 2023 16h01 HE
|
Vera Therapeutics
BRISBANE, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera”), a late-stage biotechnology company focused on developing and commercializing transformative treatments for...
Vera Therapeutics Releases 36 Week Interim Analysis of Phase 2b Clinical Trial of Atacicept for the Treatment of IgA Nephropathy; Patients in the 150 mg Dose Group Achieved a Delta of 48% Versus Placebo in Mean Reduction in Proteinuria
30 janv. 2023 06h00 HE
|
Vera Therapeutics
Vera continuing plans to rapidly advance atacicept into a pivotal Phase 3 trial in 1H 2023; full data to be presented at upcoming medical congresses Company plans to prioritize and focus current...
Vera Therapeutics Hosting a Key Opinion Leader Webinar on Atacicept for the Treatment IgA Nephropathy (IgAN)
25 janv. 2023 08h00 HE
|
Vera Therapeutics
BRISBANE, Calif., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for...
Vera Therapeutics Announces Positive Topline Results of Phase 2b ORIGIN Clinical Trial of Atacicept for the Treatment of IgA Nephropathy
03 janv. 2023 16h01 HE
|
Vera Therapeutics
Atacicept met primary endpoint at 24 weeks, and also achieved statistical significance in the 150 mg dose group with a 33% mean reduction in proteinuria from baseline, with available data showing...
Vera Therapeutics to Participate in the 41st Annual J.P. Morgan Healthcare Conference
20 déc. 2022 16h05 HE
|
Vera Therapeutics
BRISBANE, Calif., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for...
Vera Therapeutics to Present at Upcoming Investor Conferences
22 nov. 2022 07h30 HE
|
Vera Therapeutics
BRISBANE, Calif., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for...